T 1439/09 (Sclerostin/UCB PHARMA) of 16.04.2013
- European Case Law Identifier
- ECLI:EP:BA:2013:T143909.20130416
- Date of decision
- 16 April 2013
- Case number
- T 1439/09
- Petition for review of
- -
- Application number
- 99963986.7
- IPC class
- C07K 14/51A61K 39/395C07K 16/22
- Language of proceedings
- English
- Distribution
- Distributed to board chairmen (C)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Compositions and methods for increasing bone mineralization
- Applicant name
- UCB Pharma S.A.
- Opponent name
- ELI LILLY AND COMPANY
- Board
- 3.3.08
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 111(1)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 83Rules of procedure of the Boards of Appeal Art 13(3)
- Keywords
- Anonymous third party observations (deemed not to have been filed (see points 1.7, 1.8))
Sufficiency of disclosure (yes), novelty (yes), inventive step (yes) - Catchword
- -
ORDER
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the department of first instance with the order to maintain the patent on the basis of claims 1 to 41 of the Main Request filed at the oral proceedings before the board and a description to be adapted thereto.